slide 1

Back to the List of the Granted Patents                                                Click here to download AP2672 PDF

(11)    Patent No :    AP 2672    (73) Applicant(s)       
(21)    Application No :    AP/P/2007/004104    MYLAN LABORATORIES, INC., 781 Chestnut Ridge Road,       
            Morgantown, WV 26504,       
(22)    Filing Date :    30.01.2006    United States of America       
(24)    Date of Grant &    23.05.2013           
(45)    Publication :

(30)  Priority Data    (72) Inventors

    (33) Country    (31) Number    (32) Date    DUNCAN Joseph, United States of America   
    US            60/648,552        31.01.2005    O'DONNELL John P, United States of America   
    US            60/755,755        03.01.2006       
                            OWENS Walter, United States of America   
                                et al       
                                (74) Representative   
(84)    Designated State                   
    BW    GM    GH    KE    LS    MW    MZ   NA   SL    GALLOWAY & COMPANY   
    SD    SZ    T Z    UG    ZM    ZW        ZIMBABWE       
(51)    International    Classification    C07H 7/033 (2006.01)    A61K 31/7012 (2006.01)   
                            A61P 9/00 (2006.01)    A61P 9/08 (2006.01)
(54)    Title

Glucuronidated nebivolol metabolites

(57)    Abstract

This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol an d/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuroninated metabolite of nebivolol. This invention may also be used in conjuction with or as a single treatment of metabolic syndrome disorders.

(56)    Documents Cited :    RITTER JOSEPH K    EP 0 334 429    COCKCROFT JOHN    BROEDERS MARTIJN A W et al


Join our newsletter for CIPIT news through subscriptions!


Social Media


Contact Us

TEL : (254) 703 034 612